Core Viewpoint - The innovative drug concept stocks experienced a significant rally on October 31, with multiple stocks reaching their daily limit up or showing substantial gains, indicating a strong market sentiment towards the pharmaceutical sector [1]. Group 1: Stock Performance - Sangfor Health (三生国健) surged by 20% to a price of 72.96 [2] - Shuyou Shen (舒泰神) increased by 14.29% to 36.47 [2] - Tuo Jing Life (透景生命) rose by 11.97% to 24.78 [2] - Maiwei Biotechnology (迈威生物-U) gained 11.69% to 47.23 [2] - Zejing Pharmaceutical (泽璟制药-U) climbed 11.06% to 99.18 [2] - Rongchang Biopharmaceutical (荣昌生物) went up by 10.87% to 98.30 [2] - Other notable gainers included Haitai Biotechnology (海特生物) at +10.33% and Weiguan Biotechnology (微感生物) at +10.19% [2]. Group 2: Hong Kong Market Performance - Fosen Pharmaceutical (福森药业) saw a remarkable increase of 53.62% to 1.060 [3] - Yingtou Biotechnology (映图生物-B) rose by 12.44% to 318.200 [3] - Yaojie Jiankang (药捷家康-B) increased by 9.45% to 190.000 [3] - Other stocks such as Innovent Biologics (信达生物) and Jinfang Pharmaceutical (劲方医药) also experienced gains of 8.18% and 8.05% respectively [3].

Core Viewpoint - Fosun Pharma's stock surged nearly 74% during trading, currently up 49.28% at HKD 1.03, with a trading volume of HKD 10.37 million following the approval of its drug application by the National Medical Products Administration of China [1] Group 1: Drug Approvals - Fosun Pharma's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval for its "Enzalutamide Soft Capsule" for treating high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients after androgen deprivation therapy (ADT) failure [1] - The company also announced that its product, Metformin and Empagliflozin Tablets (I), is expected to win a bid in the recently published results of China's 11th national centralized drug procurement [1] Group 2: Recent Developments - In September, Fosun Pharma disclosed that its "Metformin and Empagliflozin Tablets (I)" received approval from the National Medical Products Administration of China for market launch [1]

Core Viewpoint - Fosun Pharma (01652) experienced a significant stock price increase, rising nearly 74% during trading, with a current increase of 49.28% to HKD 1.03, and a trading volume of HKD 10.37 million [1] Group 1: Product Approvals - The company's wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration of China for the listing application of "Enzalutamide Soft Capsules" [1] - The approved indications include treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients who have not received chemotherapy after androgen deprivation therapy (ADT) failure [1] Group 2: Other Product Developments - Fosun Pharma announced that its product Metformin and Ertugliflozin Tablets (I) has been proposed for winning the bid in the recently published results of the 11th batch of national centralized drug procurement in China [1] - The company previously announced in September that the listing application for "Metformin and Ertugliflozin Tablets (I)" has also been approved by the National Medical Products Administration of China [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of China for the listing application of Enzalutamide soft capsules, which are indicated for the treatment of high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and symptomatic or asymptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients who have failed androgen deprivation therapy (ADT) [1] Group 1 - Enzalutamide is an androgen receptor inhibitor that acts on the androgen receptor signaling pathway, competitively inhibiting the binding of androgens to androgen receptors, thereby suppressing androgen receptor nuclear translocation and the interaction between androgen receptors and DNA [1] - The primary metabolite of Enzalutamide, N-desmethyl-Enzalutamide, exhibits similar in vitro activity to Enzalutamide [1] - Enzalutamide has been shown to inhibit the proliferation of prostate cancer cells and induce apoptosis in vitro, and it can reduce tumor volume in mouse models of prostate cancer xenografts [1]

Core Viewpoint - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration of China for the listing application of Enzalutamide soft capsules, indicating a significant advancement in the treatment options for specific prostate cancer patients [1] Group 1: Product Approval - The approved indication for Enzalutamide includes treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients [1] - It is also approved for asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adult patients who have failed androgen deprivation therapy (ADT) and have not received chemotherapy [1] Group 2: Mechanism of Action - Enzalutamide acts as an androgen receptor inhibitor, targeting the androgen receptor signaling pathway by competitively inhibiting the binding of androgens to the androgen receptor [1] - The drug suppresses androgen receptor nuclear translocation and the interaction between the androgen receptor and DNA [1] - The primary metabolite, N-desmethyl-Enzalutamide, exhibits similar in vitro activity to Enzalutamide [1] Group 3: Efficacy - In vitro studies show that Enzalutamide can inhibit the proliferation of prostate cancer cells and induce apoptosis in these cells [1] - In mouse models of prostate cancer xenografts, Enzalutamide has been shown to reduce tumor volume [1]

Core Viewpoint - Fosen Pharmaceutical's subsidiary has received approval from the National Medical Products Administration of China for the marketing application of Enzalutamide soft capsules, targeting specific types of prostate cancer [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has developed Enzalutamide soft capsules [1] - The approved indications include treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults who have not received chemotherapy after androgen deprivation therapy (ADT) failure [1] Industry Summary - Prostate cancer is the second most common malignancy among men globally and the fifth leading cause of cancer-related deaths [1] - The incidence of prostate cancer in China is lower than in Western countries but has been increasing in recent years [1] - Enzalutamide is an androgen receptor inhibitor that competes with androgens for binding to androgen receptors, inhibiting their nuclear translocation and interaction with DNA [1] - Enzalutamide has shown efficacy in inhibiting prostate cancer cell proliferation and inducing cell death in vitro, and it has reduced tumor volume in mouse models of prostate cancer [1] - Enzalutamide was first launched in the United States in 2012, followed by the European Union in 2013, and was approved for use in China in 2019 [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 「恩扎盧胺軟膠囊」獲批上市 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團之全資附屬公司嘉亨（ 珠海橫琴 ）醫藥科技有限公司研發的「恩 扎 盧 胺 軟 膠 囊」， 上 市 申 請 已 獲 得 中 華 人 民 共 和 國 國 家 藥 品 監 督 管 理 局 批 准 ， 批 准 用 於 以 下 疾 病 的 治 療 ： 有 高 危 轉 移 風 險 的 非 轉 移 性 去 勢 抵 抗 性 前 列 腺 癌 (NM - CRPC)成年患者；雄激素剝奪治療(ADT)失敗後無症狀或有輕微症狀且未接受化療 的轉移性去勢抵抗性前列腺癌( ...

Group 1 - The core point of the article is that Fosen Pharmaceutical (01652) announced that one of its products, Metformin and Empagliflozin Tablets (containing 500mg Metformin Hydrochloride and 5mg Empagliflozin), is expected to win a bid in China's 11th national centralized drug procurement tender scheduled for October 27, 2025 [1] Group 2 - The product involved in the tender is a combination of Metformin and Empagliflozin, which are commonly used in the treatment of type 2 diabetes [1] - Winning the bid could enhance the company's market presence and sales potential in the competitive pharmaceutical landscape in China [1] - The announcement reflects the company's ongoing efforts to expand its product portfolio and participate in national procurement initiatives [1]

Core Viewpoint - Fosen Pharmaceutical (01652.HK) announced that one of its products, Metformin and Ertugliflozin Tablets (containing 500mg Metformin Hydrochloride and 5mg Ertugliflozin), is expected to win a bid in China's 11th national centralized drug procurement on October 27, 2025 [1] Group 1 - Fosen Pharmaceutical is participating in the 11th round of national drug procurement in China [1] - The product involved in the bidding is a combination of Metformin and Ertugliflozin [1] - The specific formulation includes 500mg of Metformin Hydrochloride and 5mg of Ertugliflozin [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 全國藥品集中採購擬中選結果 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣布，於二零二五年十月二十七日的中國第十一批全國藥品集中採購招標結 果中，本集團其中一個產品擬中標：二甲雙胍恩格列淨片(I)（ 鹽酸二甲雙胍500mg 和恩格列淨5 mg ）。 承董事會命 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展 情況。 福森藥業有限公司 主席兼執行董事 曹智銘先生 香港，2025年10月30日 於 本 公 告 日 期 ， 本 公 司 董 事 會 包 括 執 行 董 事 曹 智 銘 先 生（ 主 席 ）、 侯 ...